Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 14,935 matching trials from the live ClinicalTrials.gov search.
Conditions
Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8
Interventions
Non-Interventional Study
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Pancreatic Cancer
Interventions
fluorouracil, gemcitabine hydrochloride, leucovorin calcium, oxaliplatin, adjuvant therapy, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Hepatitis B, Chronic
Interventions
Tenofovir Alafenamide
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Palo Alto, California • San Jose, California
Conditions
Sickle Cell Disease, Transfusion Dependent Alpha- or Beta- Thalassemia, Diamond Blackfan Anemia, Paroxysmal Nocturnal Hemoglobinuria, Glanzmann Thrombasthenia, Severe Congenital Neutropenia, Shwachman-Diamond Syndrome, Non-Malignant Hematologic Disorders
Interventions
Reduced Toxicity Ablative Regimen, Reduced Intensity Preparative Regimen, Myeloablative Preparative Regimen
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Metastatic Colorectal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions
Durvalumab, Radiation Therapy, Tremelimumab
Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
41
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 29 more
Conditions
Cystic Fibrosis, Irritable Bowel Syndrome, Chronic Pain
Interventions
Use of neurostimulation device
Device
Lead sponsor
St. Louis University
Other
Eligibility
11 Years to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Hepatitis C, Heroin Dependence
Interventions
Buprenorphine/naloxone, pegInterferon
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Oakland, California
Conditions
Anal Cancer
Interventions
HspE7
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
San Francisco, California
Conditions
Gastroesophageal Reflux
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 80 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Maywood, Illinois • Lebanon, New Hampshire • Chapel Hill, North Carolina
Conditions
Metastatic Pancreatic Neuroendocrine Tumor, Pancreatic Neoplasm, Stage III Pancreatic Neuroendocrine Tumor AJCC v8, Stage IV Pancreatic Neuroendocrine Tumor AJCC v8, Unresectable Pancreatic Neuroendocrine Tumor
Interventions
Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Positron Emission Tomography, Sunitinib Malate
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
9
States / cities
Duarte, California • Irvine, California • Orange, California + 4 more
Conditions
Esophagitis, Pneumonitis, Non-Small Cell Lung Carcinoma
Interventions
Amifostine
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
24
States / cities
Los Angeles, California • Sacramento, California • Torrington, Connecticut + 21 more
Conditions
Acute Liver Failure, Mitochondrial Diseases, End Stage Liver Disease, Respiratory Chain Deficiencies, Mitochondrial, Disorder of Fatty Acid Oxidation
Interventions
Not listed
Lead sponsor
Arbor Research Collaborative for Health
Other
Eligibility
Up to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2029
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Herpes Zoster
Interventions
Shingrix
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Biliary Tract Cancer, Biliary Tract Neoplasms
Interventions
Nivolumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
3
States / cities
Duarte, California • Tampa, Florida • Atlanta, Georgia
Conditions
Cirrhosis, Hepatocellular Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Placebo Administration, Questionnaire Administration, Simvastatin
Procedure · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois
Conditions
Hepatitis C
Interventions
miravirsen, saline
Drug
Lead sponsor
Santaris Pharma A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Acute Pancreatitis
Interventions
Not listed
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
13
States / cities
Los Angeles, California • Stanford, California • Gainesville, Florida + 8 more
Conditions
Diabetes Mellitus, Diabetes Mellitus Complications, Gastroparesis
Interventions
Relamorelin, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
70
States / cities
Dothan, Alabama • Huntsville, Alabama • Tucson, Arizona + 58 more
Conditions
Advanced Solid Tumor
Interventions
BNT317 DL1, BNT317 DL2, BNT317 DL3, BNT317 DL4, BNT317 DL5, BNT317 DL6, BNT317 selected DLA, BNT317 selected DLB, SoC chemotherapy 1, SoC chemotherapy 2
Biological · Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
7
States / cities
Louisville, Kentucky • Grand Rapids, Michigan • Huntersville, North Carolina + 4 more
Conditions
Primary Biliary Cholangitis
Interventions
K-808 (Dose A), K-808 (Dose B), Placebo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
21
States / cities
Tucson, Arizona • Coronado, California • Los Angeles, California + 18 more
Conditions
Diarrhea, Travelers Diarrhea, Infectious Diarrhea
Interventions
Travelan, Placebo
Biological · Other
Lead sponsor
Immuron Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Parkinson's Disease
Interventions
LUBIPROSTONE
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 85 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Tampa, Florida • Houston, Texas
Conditions
Pancreatic Cancer
Interventions
dasatinib, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 8 more